AmerisourceBergen Structures Operating Model & Executive Leadership Team to Offer a More Cohesive & Unified Customer Experien...
June 19 2017 - 6:30AM
Business Wire
Expertise and Services Combined into New
“Pharmaceutical Distribution and Strategic Global Sourcing” and
“Global Commercialization Services and Animal Health” Groups
AmerisourceBergen (NYSE: ABC) today announced a new
organizational structure designed to further align the organization
to its customer needs in a more seamless and unified way, while
supporting corporate strategy and accelerating growth. The
Company’s customer-facing offerings will now be aligned under two
groups:
- Pharmaceutical Distribution and
Strategic Global Sourcing – Will be led by Group President
Robert P. Mauch, Pharm.D., Ph.D., and includes the Company’s
services to retail chain and independent pharmacies, health
systems, physician practices and alternate care sites as well as
AmerisourceBergen’s sourcing, repackaging and specialty pharmacy
capabilities. Peyton Howell will assume a new role as President,
Health Systems, Physician Practices and Strategic Health
Solutions
- Global Commercialization Services
and Animal Health – Will be led by Group President
James F. Cleary, Jr., and includes the Company’s
solutions for product commercialization and patient access, as well
as international development and animal health
“AmerisourceBergen has assembled and built best-in-class
capabilities to support every stage of pharmaceutical care, with
the goal of ensuring access to medicines that create healthier
futures for patients,” said Steven H. Collis, Chairman, President
and Chief Executive Officer of AmerisourceBergen. “This strategy
has served as the engine of AmerisourceBergen’s success and we are
now evolving our organization to capitalize on our unique portfolio
of services. Our vision is to accelerate AmerisourceBergen’s
corporate growth by further aligning our operating model to the
dynamic customer needs in the health and pharmaceutical
industry.”
For financial reporting purposes, AmerisourceBergen operations
will continue to be comprised of the Pharmaceutical Distribution
Services reportable segment and Other.
AmerisourceBergen has also formed a new management committee to
enable quicker, cross-functional decision-making. This senior
executive group includes:
- Steven H. Collis, Chairman, President
and Chief Executive Officer
- John G. Chou, Chief Legal and Business
Officer, who will now have responsibility for legal and regulatory
affairs along with strategy, innovation and business development
led by Sun Park, Executive Vice President, Strategy and Business
Development, as well as information technology led by Dale
Danilewitz, Executive Vice President and Chief Information
Officer
- Gina K. Clark, Chief Communications and
Administration Officer, who will now have responsibility for
marketing and communication and corporate citizenship and
sustainability along with human resources led by Kathy H. Gaddes,
Executive Vice President and Chief Human Resources Officer,
government affairs led by Rita Norton, Senior Vice President,
Government Affairs and Public Policy
- James F. Cleary, Jr., Group President,
Global Commercialization Services and Animal Health
- Tim G. Guttman, Chief Financial
Officer
- Robert P. Mauch, Group President,
Pharmaceutical Distribution and Strategic Global Sourcing
After 10 years of service with a track record of exceptional
integrity, leadership and performance, James Frary, previously
Executive Vice President and President, AmerisourceBergen Specialty
Group (ABSG), has decided to pursue new opportunities outside of
AmerisourceBergen. Frary will be available to support the
organization over the next few months as he transitions from his
role.
“We are better positioned to meet the needs of the marketplace
because of James’ leadership and I’m truly grateful for his
guidance and partnership over the past decade,” said Collis. “We
will carry that industry leadership into our new management
committee structure. This group will be singularly focused on
aligning every aspect of AmerisourceBergen to our purpose,
corporate strategy and continued growth. We believe this next
evolution of AmerisourceBergen will enable the Company to be more
nimble and effective, actively supporting our customers as they
grow and unlock the full value of their businesses.”
About AmerisourceBergen
AmerisourceBergen provides pharmaceutical products,
value-driving services and business solutions that improve access
to care. Tens of thousands of healthcare providers, veterinary
practices and livestock producers trust us as their partner in the
pharmaceutical supply chain. Global manufacturers depend on us for
services that drive commercial success for their products. Through
our daily work—and powered by our 19,000 associates—we are united
in our responsibility to create healthier futures.
AmerisourceBergen is ranked #11 on the Fortune 500, with more than
$145 billion in annual revenue. The company is headquartered in
Valley Forge, Pa. and has a presence in 50+ countries. Learn more
at amerisourcebergen.com.
AmerisourceBergen's Cautionary Note Regarding Forward-Looking
Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Words such as "expect," "likely," "outlook,"
"forecast," "would," "could," "should," "can," "will," "project,"
"intend," "plan," "continue," "sustain," "synergy," "on track,"
"believe," "seek," "estimate," "anticipate," "may," "possible,"
"assume," variations of such words, and similar expressions are
intended to identify such forward-looking statements. These
statements are based on management's current expectations and are
subject to uncertainty and change in circumstances. These
statements are not guarantees of future performance and are based
on assumptions that could prove incorrect or could cause actual
results to vary materially from those indicated. Among the factors
that could cause actual results to differ materially from those
projected, anticipated, or implied are the following: unfavorable
trends in brand and generic pharmaceutical pricing, including in
rate or frequency of price inflation or deflation; competition and
industry consolidation of both customers and suppliers resulting in
increasing pressure to reduce prices for our products and services;
changes in pharmaceutical market growth rates; substantial defaults
in payment, material reduction in purchases by or the loss,
bankruptcy or insolvency of a major customer; changes to the
customer or supplier mix; the retention of key customer or supplier
relationships under less favorable economics or the adverse
resolution of any contract or other dispute with customers or
suppliers; changes to customer or supplier payment terms; the
disruption of AmerisourceBergen's cash flow and ability
to return value to its stockholders in accordance with its past
practices; risks associated with the strategic, long-term
relationship between Walgreens Boots Alliance,
Inc. and AmerisourceBergen, including with respect to the
pharmaceutical distribution agreement and/or the global sourcing
arrangement; changes in the United States healthcare and
regulatory environment, including changes that could impact
prescription drug reimbursement
under Medicare and Medicaid; increasing governmental
regulations regarding the pharmaceutical supply channel and
pharmaceutical compounding; federal and state government
enforcement initiatives to detect and prevent suspicious orders of
controlled substances and the diversion of controlled substances;
federal and state prosecution of alleged violations of related laws
and regulations, and any related litigation, including shareholder
derivative lawsuits or other disputes relating to our distribution
of controlled substances; increased federal scrutiny and qui tam
litigation for alleged violations of fraud and abuse laws and
regulations and/or any other laws and regulations governing the
marketing, sale, purchase and/or dispensing of pharmaceutical
products or services and any related litigation; material adverse
resolution of pending legal proceedings; declining reimbursement
rates for pharmaceuticals; the acquisition of businesses that do
not perform as expected, or that are difficult to integrate or
control, including the integration of PharMEDium, or the inability
to capture all of the anticipated synergies related thereto;
regulatory action in connection with the production, labeling or
packaging of products compounded by our compounded sterile
preparations (CSP) business; declining economic conditions
in the United States and abroad; financial market
volatility and disruption; the loss, bankruptcy or insolvency of a
major supplier; interest rate and foreign currency exchange rate
fluctuations; managing foreign expansion, including non-compliance
with the U.S. Foreign Corrupt Practices Act, anti-bribery laws and
economic sanctions and import laws and regulations; malfunction,
failure or breach of sophisticated information systems to operate
as designed; risks generally associated with data privacy
regulation and the international transfer of personal data; changes
in tax laws or legislative initiatives that could adversely
affect AmerisourceBergen's tax positions and/or
AmerisourceBergen’s tax liabilities or adverse resolution of
challenges to AmerisourceBergen's tax positions; natural
disasters or other unexpected events that
affect AmerisourceBergen's operations; the impairment of
goodwill or other intangible assets, resulting in a charge to
earnings; and other economic, business, competitive, legal, tax,
regulatory and/or operational factors
affecting AmerisourceBergen's business generally. Certain
additional factors that management believes could cause actual
outcomes and results to differ materially from those described in
forward-looking statements are set forth (i) in Item 1A (Risk
Factors) in the Company’s Annual Report on Form 10-K for the fiscal
year ended September 30, 2016 and elsewhere in that
report and (ii) in other reports filed by the Company pursuant to
the Securities Exchange Act.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170619005336/en/
AmerisourceBergen CorporationMediaGabe
WeissmanVice President, Communications610-727-3696 –
Office267-438-7998 –
Mobilegweissman@amerisourcebergen.comorInvestorsKeri
P. MattoxVice President, Corporate & Investor
Relations610-576-7801 – Office610-427-9280 –
Mobilekmattox@amerisourcebergen.comorBennett S.
MurphyDirector, Corporate & Investor
Relations610-727-3693 – Office610-209-5691 –
Mobilebmurphy@amerisourcebergen.com
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024